We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ECCC:NYSEEagle Point Credit Company Inc. 6.50% Series C Term Preferred Stock due 2031 Analysis

Data as of 2026-03-30 - not real-time

$24.55

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Eagle Point Credit Company Inc. (ECCC) trades at $24.55, just above its 20‑day SMA (24.30) and 200‑day SMA (23.85), with a bullish MACD histogram (+0.043) and a neutral RSI (56). The stock benefits from a high dividend yield of 6.62%, but the payout ratio is effectively zero and operating cash flow is negative, raising concerns about dividend sustainability. Valuation metrics show a PE of 13.46, below the industry average of 16.25, yet the price‑to‑book multiple of 4.31 suggests the market is pricing the stock above its book value. The balance sheet is heavily leveraged (debt‑to‑equity ~39.5) and profitability is weak, reflected in a -56% profit margin and negative ROE. Volume is decreasing and 30‑day volatility sits at 9.2%, while beta is exceptionally low (~0.08), indicating limited market‑wide price swings.
Overall, the technical picture is modestly bullish, but fundamental weaknesses—especially high leverage and unsustainable dividend policy—temper optimism. Investors should weigh the attractive yield against the risk of earnings deterioration and potential dividend cuts.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near short‑term resistance at $24.75
  • Bullish MACD and RSI in neutral zone
  • High dividend yield but questionable sustainability

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Continued leverage pressure (Debt/Equity ~39.5)
  • Negative operating cash flow
  • Potential for dividend adjustment

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Weak profitability and negative ROE
  • Elevated debt levels relative to cash
  • Unsustainable dividend policy may erode shareholder value

Key Metrics & Analysis

Financial Health

Revenue Growth3.30%
Profit Margin-56.38%
P/E Ratio13.5
ROE-11.24%
ROA6.45%
Debt/Equity39.51
P/B Ratio4.3
Op. Cash Flow$-21421216
Free Cash Flow$66.4M
Industry P/E16.2

Technical Analysis

TrendNeutral
RSI56.5
Support$23.26
Resistance$24.75
MA 20$24.30
MA 50$24.41
MA 200$23.85
MACDBullish
VolumeDecreasing
Fear & Greed Index67.73

Valuation

GradeFair
TypeValue
Dividend Yield6.62%

Risk Assessment

Beta0.08
Volatility9.22%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.